Skip to content
2000
Volume 13, Issue 35
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angiogenesis inhibitors to find their molecular targets. Both approaches may lead to the development of angiostatic therapies that are directly targeted towards activated endothelial cells. This review summarizes the recent developments in both approaches.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161207782794121
2007-12-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161207782794121
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test